NASDAQ:STTK Shattuck Labs (STTK) Stock Price, News & Analysis $6.10 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$5.25 -0.85 (-13.92%) As of 05/22/2026 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Shattuck Labs Stock (NASDAQ:STTK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Shattuck Labs alerts:Sign Up Key Stats Today's Range$6.00▼$6.3950-Day Range$5.79▼$7.8852-Week Range$0.71▼$8.33Volume338,663 shsAverage Volume573,273 shsMarket Capitalization$467.75 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingModerate Buy Company Overview Shattuck Labs, Inc. (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier. The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities. Preclinical studies have demonstrated that vaccinated animals produce robust anti‐fentanyl antibody titers and are protected against lethal and sublethal fentanyl challenges. Shattuck Labs is advancing its vaccine candidate through IND‐enabling studies and plans to initiate first‐in‐human trials to evaluate safety, immunogenicity, and its potential to block the psychoactive effects of fentanyl. Founded in 2017, Shattuck Labs was established to address the growing public health crisis posed by opioid misuse and overdose. The company leverages insights from immunology and vaccinology, collaborating with academic partners and contract manufacturing organizations to streamline development and scale up production. Shattuck Labs serves the U.S. market and is preparing for broader geographic reach as its clinical programs progress. Shattuck Labs is led by Chief Executive Officer Craig H. Wheeler, who brings extensive experience in biopharmaceutical R&D and commercial strategy. The management team includes experts in vaccine formulation, regulatory affairs, and translational medicine. Through its focused pipeline and innovative platform, Shattuck Labs aims to pioneer a new class of non‐addictive, immunotherapeutic treatments for substance use disorders.AI Generated. May Contain Errors. Read More Shattuck Labs Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreSTTK MarketRank™: Shattuck Labs scored higher than 61% of companies evaluated by MarketBeat, and ranked 357th out of 869 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingShattuck Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 7 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialShattuck Labs has a consensus price target of $13.00, representing about 113.1% upside from its current price of $6.10.Amount of Analyst CoverageShattuck Labs has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Shattuck Labs' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Shattuck Labs are expected to decrease in the coming year, from ($0.51) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Shattuck Labs is -9.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Shattuck Labs is -9.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioShattuck Labs has a P/B Ratio of 4.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Shattuck Labs' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.02% of the float of Shattuck Labs has been sold short.Short Interest Ratio / Days to CoverShattuck Labs has a short interest ratio ("days to cover") of 3.28, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Shattuck Labs has recently increased by 5.95%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldShattuck Labs does not currently pay a dividend.Dividend GrowthShattuck Labs does not have a long track record of dividend growth. News and Social Media1.5 / 5News Sentiment-0.59 News SentimentShattuck Labs has a news sentiment score of -0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Shattuck Labs this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Shattuck Labs to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Shattuck Labs insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $212,544.00 in company stock.Percentage Held by Insiders8.79% of the stock of Shattuck Labs is held by insiders.Percentage Held by Institutions58.74% of the stock of Shattuck Labs is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Shattuck Labs' insider trading history. Receive STTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Shattuck Labs and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. STTK Stock News HeadlinesShattuck Labs (NASDAQ:STTK) Cut to Hold at Wall Street ZenMay 23 at 1:40 AM | americanbankingnews.comShattuck Labs: Priced As If Risk Was Not A Part Of The EquationMay 22 at 2:54 PM | seekingalpha.comSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a $1.75 trillion IPO - larger than Saudi Aramco and any tech offering in history. CNBC calls it 'the big market event of 2026.' According to former tech executive and angel investor Jeff Brown, there's a way to claim a stake before the public filing drops, starting with as little as $500.May 25 at 1:00 AM | Brownstone Research (Ad)Shattuck Labs (NASDAQ:STTK) Insider Sells $14,244.32 in StockMay 15, 2026 | insidertrades.comWe're Not Very Worried About Shattuck Labs' (NASDAQ:STTK) Cash Burn RateMay 11, 2026 | finance.yahoo.comShattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | finanznachrichten.deShattuck Labs Reports First Quarter 2026 Financial Results and Recent Business HighlightsMay 7, 2026 | globenewswire.comCantor Fitzgerald Initiates Coverage of Shattuck Labs (STTK)May 1, 2026 | insidermonkey.comSee More Headlines STTK Stock Analysis - Frequently Asked Questions How have STTK shares performed this year? Shattuck Labs' stock was trading at $3.65 at the beginning of the year. Since then, STTK shares have increased by 67.1% and is now trading at $6.10. How were Shattuck Labs' earnings last quarter? Shattuck Labs, Inc. (NASDAQ:STTK) announced its earnings results on Thursday, May, 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.01. When did Shattuck Labs IPO? Shattuck Labs (STTK) raised $178 million in an initial public offering (IPO) on Friday, October 9th 2020. The company issued 11,882,352 shares at $14.00-$16.00 per share. Citigroup, Cowen and Evercore ISI acted as the underwriters for the IPO and Needham & Co. was co-manager. Who are Shattuck Labs' major shareholders? Shattuck Labs' top institutional investors include Renaissance Technologies LLC (0.79%), Dimensional Fund Advisors LP (0.21%), The Manufacturers Life Insurance Company (0.19%) and Bank of New York Mellon Corp (0.12%). Insiders that own company stock include Redmile Group, Llc, Orbimed Advisors Llc, Mona Ashiya, Tyler Brous, Andrew R Neill, Arundathy N Pandite, Abhinav A Shukla, Stephen Stout and Taylor Schreiber. View institutional ownership trends. How do I buy shares of Shattuck Labs? Shares of STTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Shattuck Labs own? Based on aggregate information from My MarketBeat watchlists, some other companies that Shattuck Labs investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/07/2026Today5/25/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (8m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 STTK's financial health is in the Green zone, according to TradeSmith. STTK has been in this zone for over 8 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:STTK CIK1680367 Webwww.shattucklabs.com Phone512-900-4690FaxN/AEmployees100Year Founded2016Price Target and Rating Average Price Target for Shattuck Labs$13.00 High Price Target$25.00 Low Price Target$2.00 Potential Upside/Downside+113.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Trailing Twelve Months)($0.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.81 million Net MarginsN/A Pretax Margin-4,987.40% Return on Equity-60.73% Return on Assets-55.75% Debt Debt-to-Equity RatioN/A Current Ratio22.07 Quick Ratio22.06 Sales & Book Value Annual Sales$1 million Price / Sales467.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.25 per share Price / Book4.88Miscellaneous Outstanding Shares76,680,000Free Float69,941,000Market Cap$467.75 million OptionableOptionable Beta1.18 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:STTK) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Shattuck Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Shattuck Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
